Clinical Trial Update: Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

View source ↗

Summary

A completed study evaluating changes in immunoglobulin levels in patients with relapsing multiple sclerosis treated with anti-CD20 therapies, sponsored by Novar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome
• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)
• Ofatumumab (ofatumumab)
• Rituximab (rituximab)

Snippet

Sponsor: Novartis | Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Status: COMPLETED